Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Core Insights - U.S. telehealth firm Ro has initiated a research collaboration with drugmaker Amgen to address the challenges faced by patients and providers in accessing obesity treatments, particularly focusing on GLP-1 medications [1] Group 1 - The collaboration aims to explore the barriers to accessing obesity treatments, which is a growing concern in the healthcare industry [1] - Ro's partnership with Amgen highlights the increasing importance of telehealth solutions in managing chronic conditions like obesity [1] - The research will likely provide insights that could enhance patient access to effective obesity treatments, potentially impacting market dynamics [1]